Citigroup Inc Jounce Therapeutics, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$0.64 - $1.99 $625 - $1,944	-977 Reduced 69.69%	425 $0
Q3 2022 Nov 10, 2022	SELL	$2.73 - $4.92 $149,579 - $269,571	-54,791 Reduced 97.51%	1,402 $3,000
Q2 2022 Aug 10, 2022	BUY	$2.8 - $7.67 $150,278 - $411,656	53,671 Added 2128.11%	56,193 $170,000
Q1 2022 May 12, 2022	SELL	$6.01 - $8.54 $44,173 - $62,768	-7,350 Reduced 74.45%	2,522 $17,000
Q4 2021 Feb 10, 2022	BUY	$7.11 - $9.64 $24,906 - $33,768	3,503 Added 55.0%	9,872 $82,000
Q3 2021 Nov 10, 2021	BUY	$5.04 - $8.73 $32,099 - $55,601	6,369 New	6,369 $47,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.